Advancements in Incremental Care in Glaucoma

New mechanisms of action, new delivery methods, and greater durability will continue to improve patient outcomes.

By: Douglas J. Rhee, MD

Glaucoma Physician January 1, 2026 Page(s): 14-15

Clinical Report: Advancements in Incremental Care in Glaucoma

Overview

Recent advancements in glaucoma management emphasize incremental care, integrating new therapies and delivery methods to enhance patient outcomes. The shift from traditional multiple drop regimens to innovative treatments like selective laser trabeculoplasty and novel pharmacologic agents is crucial for improving adherence and efficacy.

Background

Glaucoma remains a leading cause of preventable vision loss, necessitating effective management strategies. Historically, treatment involved escalating topical therapies, often leading to adherence challenges and systemic safety concerns. New approaches, including laser therapies and novel medications, are essential to optimize intraocular pressure (IOP) control and patient quality of life.

Data Highlights

No numerical data presented in the source material.

Key Findings

Selective laser trabeculoplasty (SLT) is a cost-effective first-line treatment for glaucoma, reducing the need for incisional surgery.
Prostaglandin analogs (PGAs) remain a cornerstone of topical therapy, providing significant IOP reduction with minimal systemic side effects.
QLS-111, an ATP-sensitive potassium channel opener, demonstrated a mean IOP reduction of 3.7 mmHg in phase 2 studies.
New sustained-release (SR) drug delivery systems, such as bimatoprost SR and travoprost implants, aim to improve patient adherence by reducing the frequency of drop instillations.
Rho kinase inhibitors have shown promise as incremental therapies, although their side effect profiles may limit long-term use.

Clinical Implications

Clinicians should consider SLT as a viable first-line treatment option for glaucoma patients, particularly those who may struggle with adherence to multiple medications. The introduction of new agents like QLS-111 and sustained-release formulations could enhance treatment efficacy while minimizing the burden of daily drop regimens.

Conclusion

The evolving landscape of glaucoma management highlights the importance of incremental care strategies that prioritize patient adherence and treatment effectiveness. Continued research and development of innovative therapies will be vital in addressing the challenges of glaucoma management.

PentaVision

Glaucoma Physician